10 results about "Antifolate" patented technology

Antibody constructs that bind human folate receptor alpha (FRα or FOLR1) and antibody-drug conjugates (ADCs) comprising an anti-FRα antibody construct conjugated to a drug, such as a cytotoxin or an immune modulator, and their use as therapeutics or diagnostics, for example, in the treatment or diagnosis of cancer.

The disclosure relates generally to gamma polyglutamated Antifolate, formulations containing liposomes filled with gamma polyglutamated Antifolate, methods of making the gamma polyglutamated Antifolate and liposome containing formulations, and methods of using polyglutamated gamma polyglutamated Antifolate and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and an autoimmune disease such as rheumatoid arthritis).

The present disclosure relates generally to polyglutamic acid-modified antifolate agents, formulations containing liposomes filled with alpha or D-gamma polyglutamic acid-modified antifolate agents, methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of treating myeloproliferative disorders (e.g., cancer) and immune system disorders (e.g., autoimmune diseases, such as rheumatoid arthritis) using the polyglutamic acid-modified antifolate and the liposomal-containing formulations.

The name of the invention is polyglutamic acid-modified antifolic acid agents and uses thereof. The present disclosure relates generally to polyglutamic acid-modified antifolate agents, formulations containing liposomes filled with polyglutamic acid-modified antifolate agents, methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of making polyglutamic acid-modified antifolate agents and liposomal-containing formulations, and methods of treating myeloproliferative disorders (e.g., cancer) and immune system disorders (e.g., autoimmune diseases, such as rheumatoid arthritis) using the polyglutamic acid-modified antifolate and the liposomal-containing formulations.

Embodiments relate to a composition for inducing differentiation of stem cells into chondrocytes, a pharmaceutical composition for treatment of cartilage injury diseases, and a sustained-release dosage form for inducing differentiation of stem cells into chondrocytes, wherein the compositions and dosage form each comprise an antifolate. Using the composition for inducing differentiation of stem cells into chondrocytes according to one embodiment, it is possible to selectively induce stem cells to differentiate into chondrocytes without inducing differentiation into other cell types.

The invention relates to the technical field of biological medicines, and particularly discloses application of a composition in preparation of anti-colorectal cancer medicines. The composition comprises an anti-folic acid drug and a pharmaceutically acceptable salt thereof, and an anti-creatine transport drug and a pharmaceutically acceptable salt thereof. Wherein the anti-folic acid medicine is used for inhibiting a folic acid-dependent nucleotide synthesis process and limiting DNA synthesis and replication of tumor cells, so that abnormal proliferation of the tumor cells is inhibited; the anti-creatine transport drug is used for inhibiting creatine uptake mediated by creatine transporter, reducing the level of phosphocreatine in cells and further weakening the energy buffering capacity and stress recovery capacity of tumor cells. According to the composition provided by the invention, two key metabolic pathways of nucleotide synthesis and energy homeostasis maintenance in colorectal cancer cells can be intervened at the same time, and dual inhibition and synergistic intervention are formed on the metabolism level, so that the inhibition effect on tumor cell proliferation and survival is enhanced; and the possibility of drug resistance of tumor cells to a single therapy through metabolic reprogramming can be reduced.

The present disclosure relates to antibody conjugates with binding specificity for folate receptor alpha (FOLR1) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.

The invention provides an antibody drug conjugate targeting folate receptor alpha, and also discloses application of the antibody drug conjugate in preparation of drugs for treating folate receptor alpha-related tumors. The antibody drug conjugate provided by the invention combines the targeting property of the anti-folate receptor alpha antibody to folate receptor alpha expression cells, the strong endocytosis effect of a target spot and the toxic effect of a small molecule chemical drug, so that an excellent tumor killing effect is achieved.

The disclosure relates generally to alpha polyglutamated Antifolates, formulations containing liposomes filled with alpha polyglutamated Antifolates, methods of making the alpha polyglutamated Antifolates and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated Antifolates and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).